Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Calypte acts to comply with FDA warning letter:

This article was originally published in Clinica

Executive Summary

Calypte Biomedical is taking action to comply with an FDA warning letter listing significant deviations from Federal regulations in the operation of its newly-acquired plant in Rockville, Maryland. The warning letter was based on inspections of the Rockville plant made in November and December 1998, when it was owned and operated by Cambridge Biotech, a subsidiary of bioMerieux Vitek. Calypte says it has responded in writing to many of points raised by the FDA and is rectifying the remaining issues.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT078331

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel